

SWISS BIOTECH SUCCESS STORY

Schlieren



GLYCART
biotechnology

Glycart Biotechnology (now Roche Glycart) recognized for its role as pioneer in antibody engineering for cancer immunotherapy

The Schlieren-based company successfully engineered antibody glycosylation to increase immune-mediated cancer cell killing. A first drug based on this technology (obinutuzumab – Gazyva – Gazyvaro) was approved in 2013 to treat chronic lymphocytic leukemia and then afterwards to treat relapsed/refractory and first line follicular non-Hodgkins lymphoma. Clinical development of Gazyva was done in Roche after Glycart's acquisition in 2005

Since 2005, Roche Glycart has grown from 29 to over 180 employees, all based in Schlieren. The site, today known as Roche Innovation Center Zurich (part of Roche's Pharma Research & Early Development organization, pRED) has become a center of excellence for cancer immunotherapy and antibody engineering with numerous new drug candidates in clinical trials



THE FOUNDING TEAM



Pablo Umaña
Co-founder




Joël Jean-Mairet
Co-founder





KNOWLEDGE

GlycoMAb works by genetically engineering the antibody-producing cells with a gene encoding an oligosaccharide-modifying enzyme
The modified cells produce new molecular variants of the antibody, bearing bisected non-fucosylated oligosaccharides
Standard production cell lines do not make these special oligosaccharides



INDICATIONS

Obinutuzumab is approved in the US and the EU for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naïve patients, and as a second line treatment for follicular lymphoma. It is also being developed in a number of additional cancer indications



PIPELINE

GlycoMAb has the potential to address major challenges:

- Expanding the therapeutic window of a given antibody
- Reducing product attrition and avoiding costly failures
- Enabling life cycle management
- Generating economically more attractive products

SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ New technology
- ★ Product approval and sustainable revenues
- ★ Important IP, innovative deal-making, acquisition
- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Swissness: Think global, made in Switzerland